Bristol-Myers Squibb Co. BMY

The Motley Fool 14 nov

The article examines five high-yield dividend stocks that appear riskier than they actually are. Pfizer and Bristol Myers Squibb face normal pharmaceutical industry headwinds from patent expirations but maintain sustainable dividends through strong cash flows. REITs Realty Income and W.P. Carey are pressured by rising interest rates, but historical market adjustments should protect profitability. Hormel Foods, despite slow turnaround progress, has strong financials and backing from the Hormel Foundation, making its dividend safer than its yield suggests.

The Motley Fool 14 nov

Bristol Myers Squibb faces upcoming patent expirations on older drugs, particularly Eliquis losing U.S. patent protection in 2028. However, the company's newer growth portfolio is already generating $7.7 billion quarterly in revenue, exceeding the $5.42 billion from legacy drugs. With a 4% dividend yield and reasonable 55% payout ratio, the stock may appeal to aggressive income investors despite near-term patent cliff risks.

The Motley Fool 13 nov

The article compares Amgen and Vertex Pharmaceuticals as investment options for 2027. Amgen offers diversified revenue streams across multiple drug franchises with lower valuation metrics but faces biosimilar competition and pricing pressures. Vertex demonstrates faster growth driven by cystic fibrosis dominance and promising pipeline candidates like Povetacicept, though at a premium valuation. The analyst recommends Vertex for long-term growth investors despite higher valuations, citing its superior growth trajectory and innovative pipeline.

Zacks Investment Research 13 nov

Bristol Myers Squibb expanded Camzyos' FDA approval to pediatric patients, broadening its addressable market in the obstructive hypertrophic cardiomyopathy space. Camzyos sales surged 61% to $1.1 billion, while Eliquis revenues rose 21% to $13.3 billion in nine months. However, BMY faces competitive pressure from Cytokinetics' newly approved Myqorzo and potential competition from Edgewise Therapeutics, while upcoming patent expirations pose longer-term revenue challenges.

Zacks Investment Research 12 nov

Replimune's stock surged 80% over the past month following FDA accelerated approval and commercial launch of Tudriqev (RP1) in combination with Bristol Myers' Opdivo for treating unresectable advanced cutaneous melanoma. Early adoption at leading melanoma centers and better-than-expected Q2 2027 earnings results drove investor confidence. The company's pipeline candidate RP2 is advancing in multiple cancer indications with preliminary results expected in Q1 2027.